MOVE Medacta Group

EQS-News: Medacta Announces First U.S. Surgery with the New M.U.S.T. LT System in Minimally Invasive Spine Surgery

EQS Group-News: Medacta Group SA / Key word(s): Product Launch
Medacta Announces First U.S. Surgery with the New M.U.S.T. LT System in Minimally Invasive Spine Surgery

28.04.2021 / 19:00


Media release

Medacta Announces First U.S. Surgery with the New M.U.S.T.(R) LT System in Minimally Invasive Spine Surgery

CASTEL SAN PIETRO, 28 April 2021 - Medacta announced today the first surgery utilizing its M.U.S.T.(R) LT, following clearance by the U.S. Food and Drug Administration (FDA). M.U.S.T. LT (Long Tab Screw System) is the new minimally invasive solution for posterior spine fixation in the percutaneous approach. Mainly focused on degenerative spine cases, M.U.S.T. LT expands the benefits of a percutaneous approach in spine deformity, tumors, and trauma applications. The first surgery employing M.U.S.T. LT has been recently performed in the U.S. by Stephen Tolhurst, M.D., at Texas Back Institute, in Plano, Texas.

"The cortico-cancellous thread pitch offered great bony purchase," said Dr. Tolhurst about the surgery. "I enjoyed the slim profile of the screw towers and instruments, which facilitated a very minimally invasive approach, while maintaining robust and easily usable instrumentation."

M.U.S.T. LT is a versatile solution giving the surgeons freedom of choice between fast locking screws, applicable in an extensive range of degenerative cases, and an extended reduction capacity, a crucial aspect in lumbar spondylolisthesis or thoracic kyphosis restoration.
The absence of Nickel, Cobalt and Chromium makes M.U.S.T. LT a unique solution within the Medacta M.U.S.T. pedicle screw system, providing full spine fixation with 100% Titanium alloy constructs.
Finally, the cortical-cancellous M.U.S.T. LT thread is designed to differentiate the bone purchase, adapting the implants to match the different bone density areas of the vertebra.

Medacta collaborates on a regular basis with internationally recognized surgeons on innovative surgical techniques and the evolution of products and methodologies. M.U.S.T. L.T. has been designed in collaboration with experts specialized in minimally invasive spine surgery. This innovative product is also supported by Medacta's M.O.R.E. Institute, which provides continuous educational and developmental support to surgeons as they work towards discovering new technologies.

With the introduction of the M.U.S.T. LT system, Medacta continues to expand its fast-growing spine portfolio, delivering innovative solutions to surgeons for the benefit of their patients.

For more information on Medacta spine surgery solutions, please visit .

Contact
Medacta International SA
Gianluca Olgiati
Senior Director Global Marketing
Phone: 0


About Medacta
Medacta is an international company specializing in the design, production, and distribution of innovative orthopaedic products, as well as in the development of accompanying surgical techniques. Established in 1999 in Switzerland, Medacta is active in joint replacement, spine surgery, and sports medicine. Medacta is committed to improving the care and well-being of patients and maintains a strong focus on healthcare sustainability. Medacta's innovation, forged by close collaboration with surgeon leaders globally, began with minimally invasive surgical techniques and has evolved into personalized solutions for every patient. Through the M.O.R.E. Institute, Medacta supports surgeons with a comprehensive and tailored program dedicated to the advancement of medical education. Medacta is headquartered in Castel San Pietro, Switzerland, and operates in over 40 countries.



End of Media Release


Language: English
Company: Medacta Group SA
Strada Regina
6874 Castel San Pietro
Switzerland
Phone:
E-mail: ,
Internet:
ISIN: CH0468525222
Listed: SIX Swiss Exchange
EQS News ID: 1189514

 
End of News EQS Group News Service

1189514  28.04.2021 

fncls.ssp?fn=show_t_gif&application_id=1189514&application_name=news&site_id=research_pool
EN
28/04/2021

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Medacta Group

Maria Vara ... (+3)
  • Maria Vara
  • Oscar Haffen Lamm
  • Valliant Campagne

Suspension of coverage

From 2nd of June we are suspending coverage of companies below due to a reallocation of resources. Our prior estimates should no longer be used as an indicator for the company moving forward.INNATE PHARMAINVENTIVAMEDACTAMEDARTISONWARD MEDICALVALNEVA

Maria Vara
  • Maria Vara

Medacta: model update - Buy rating reiterated, unchanged CHF160 PT

We update our model following the publication of the company's annual report. No changes have been applied to our revenue forecast as FY 2024 results and 2025 guidance are aligned with our estimates. On the P&L, we have softened our S&M expenses expectation as these stood more towards 35.5%

 PRESS RELEASE

Medacta publishes 2025 Annual General Meeting invitation

Medacta Group SA / Key word(s): AGMEGM Medacta publishes 2025 Annual General Meeting invitation 08.04.2025 / 10:00 CET/CEST Press Release                     Medacta publishes 2025 Annual General Meeting invitation  CASTEL SAN PIETRO, 8 April 2025 – Medacta Group SA (“Medacta”, SIX:MOVE) published today the invitation to the Annual General Meeting (“AGM”) which will take place on Wednesday, 7 May 2025 at 11.00 a.m. at the Group premises in Via alla Rossa 6, Rancate, Switzerland. Shareholders can register to attend the Annual General Meeting in person but will also be abl...

Maria Vara
  • Maria Vara

Medacta: Exceptional FY2024 to fuel sustainable growth, adj. EBITDA hi...

Medacta reported preliminary unaudited FY 2024 revenue in early February; hence, the EUR590.6m figure was not a surprise. Nonetheless, we may highlight again that all four business lines delivered above the market growth with double-digit cc gains with a broad base geographical contribution. Gross

Maria Vara
  • Maria Vara

Medacta: expanding SportsMed footprint with Parcus Medical acquisition

Medacta expands its SportMeds footprint by acquiring Parcus Medical, a distinguished player with a diverse product family in sports medicine spanning the shoulder, knee, hip, and foot & ankle, with FY2024 unaudited revenues of USD16m. The acquisition not only expands Medacta's offering but also

ResearchPool Subscriptions

Get the most out of your insights

Get in touch